Evidence map›Paper›PMID 29180093›Full record

Observational studyJournal of the American Academy of Dermatology2018

Estimating the cost of skin cancer detection by dermatology providers in a large health care system.

Martha Matsumoto, Aaron Secrest, Alyce Anderson, Melissa I Saul, Jonhan Ho, John M Kirkwood, Laura K Ferris

Abstract readObservational Study
In one paragraph

Observational study in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. An Intelligent System for Monitoring Skin Diseases.Sensors (Basel, Switzerland) · 2018
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Augmenting pigmented lesion assay results with the three-point dermoscopy checklist to improve pigmented lesion triage.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Identification of skin cancer screening visits by using claims data.Journal of the American Academy of Dermatology · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Martha MatsumotoUniversity of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Aaron SecrestDepartment of Dermatology, University of Utah, Salt Lake City, Utah.
Alyce AndersonUniversity of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Melissa I SaulDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jonhan HoDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
John M KirkwoodDepartment of Medicine, Division of Medical Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Laura K FerrisDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: ferrislk@upmc.edu.
University of Pittsburgh · USUniversity of Utah · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
NRSA Training CoreTL1TR001858 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RADOMSKI, THOMAS, RUBIO, DORIS M · 2016 to 2025
$11.1M
NCATS NIH HHS TL1 TR001858NCATS NIH HHS UL1 TR001857NCI NIH HHS P50 CA121973
6 · The paper itself

Abstract

backgroundData on the cost and efficiency of skin cancer detection through total body skin examination are scarce.

objectiveTo determine the number needed to screen (NNS) and biopsy (NNB) and cost per skin cancer diagnosed in a large dermatology practice in patients undergoing total body skin examination.

methodsThis is a retrospective observational study.

resultsDuring 2011-2015, a total of 20,270 patients underwent 33,647 visits for total body skin examination; 9956 lesion biopsies were performed yielding 2763 skin cancers, including 155 melanomas. The NNS to detect 1 skin cancer was 12.2 (95% confidence interval [CI] 11.7-12.6) and 1 melanoma was 215 (95% CI 185-252). The NNB to detect 1 skin cancer was 3.0 (95% CI 2.9-3.1) and 1 melanoma was 27.8 (95% CI 23.3-33.3). In a multivariable model for NNS, age and personal history of melanoma were significant factors. Age switched from a protective factor to a risk factor at 51 years of age. The estimated cost per melanoma detected was $32,594 (95% CI $27,326-$37,475). LIMITATIONS: Data are from a single health care system and based on physician coding.

conclusionMelanoma detection through total body skin examination is most efficient in patients ≥50 years of age and those with a personal history of melanoma. Our findings will be helpful in modeling the cost effectiveness of melanoma screening by dermatologists.

Indexed as

DermatologyHealth Care CostsAdultAgedAged, 80 and overDelivery of Health CareEarly Detection of CancerFemaleHumansMaleMiddle AgedRetrospective StudiesSkin Neoplasmsbiopsycostdetectionmelanomascreeningskin cancer

Identifiers

PMID29180093
PMCPMC5963718
OpenAlexW2770495625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.